2-Phosphorylpyrrolidines can act as fibroblast activation protein alpha (FAPα) inhibitors [27], increased content of which is observed in 90% of carcinomas [28] and which is interesting as a target for cancer therapy [29]. This evidence concerns the gene FAP and carcinoma.